Navigation Links
Neuralstem's NSI-189 Trial in Major Depressive Disorder Receives FDA Approval to Advance to Phase Ib
Date:12/27/2011

ROCKVILLE, Md., Dec. 27, 2011 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) announced that it has been approved by the Food and Drug Administration to advance to Phase Ib in its ongoing clinical trial to test its novel neuroregenerative compound, NSI-189, for the treatment of major depressive disorder (MDD). Phase Ib will test the safety and tolerability of the drug in depressed patients. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in MDD as well as other diseases and conditions, such as Alzheimer's disease and post-traumatic stress disorder (PTSD).

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

"We are pleased to be approved to begin testing NSI-189 in patients who suffer from depression," said Karl Johe, PhD, Chief Scientific Officer and Chairman of Neuralstem's Board of Directors. "Loss of hippocampal volume is a known characteristic in depressed patients. NSI-189 stimulates neurogenesis and increases hippocampal volume in healthy adult mice, at the same time reversing behavioral symptoms in mouse depression models, so it could address depression at the source."

"It is exciting to see a new class of drugs that potentially offers a novel and different approach to this disease moving into patients," said Maurizio Fava, MD, Slater Family Professor of Psychiatry at Harvard Medical School and Executive Vice Chair of the Department of Psychiatry at Massachusetts General Hospital. Dr. Fava, one of the world's leading researchers in MDD, helped design the Neuralstem trial.

About NSI-189

Neuralstem's technology enabled the creation of neural stem cell lines from many areas of the human CNS, including the hippocampus.
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Neuralstem Updates NSI-189 Major Depression Trial
2. Neuralstem Completes Phase Ia in Neuroregenerative Small Molecule Drug, NSI-189, Major Depressive Disorder Trial
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
10. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
11. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Aug. 22, 2014  As the Medical Affairs, role ... leaders in this area are exploring methods to develop ... Medical Affairs Consortium at Best Practices, LLC is designed ... insights about the key challenges they face. The consortium ... through three virtual roundtable discussions where leaders discuss key ...
(Date:8/22/2014)...  Dr. Mark Rasak , MD is recognized ... Award in the field of Medicine as a result ... Dr. Rasak has over 15 years of ... the business; overseeing the daily operations; interventional cardiology; complex ... addition, he is an honored Fellow of the American ...
(Date:8/22/2014)... --  Zacks Equity Research highlights Epizyme (Nasdaq: EPZM - ... (Nasdaq: PNRA - Free Report ) as the Bear of ... Therapeutics (Nasdaq: FOLD - Free Report ), Sanofi (NYSE: ... Free Report ). Here is a synopsis of all ... The biotech bull market is far from over ...
Breaking Medicine Technology:Best Practices' Medical Affairs Consortium Survey Has Achieved Strong Participation 2Dr. Mark Rasak, MD is recognized by Continental Who's Who with the Diamond Lifetime Achievement Award 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6
... Althea Technologies, Inc., a leading provider of development ... its inaugural Health and Wellness Fair today. The fair ... daily activities to promote physical and mental health amongst ... encouraged to participate in daily challenges and talks. Today,s ...
... 2011 Delcath Systems, Inc. (NASDAQ: DCTH ) ... Life Sciences Management Access Conference on Tuesday, August 16, 2011 ... Financial Officer, will provide an overview of the Company,s business ... this conference is by invitation only. Delcath will offer a ...
Cached Medicine Technology:Althea Technologies Hosts Health and Wellness Week 2Delcath to Present at the Wedbush 2011 Life Sciences Conference on August 16, 2011 2Delcath to Present at the Wedbush 2011 Life Sciences Conference on August 16, 2011 3
(Date:8/22/2014)... August 22, 2014 Today, Zane Benefits, ... guide on Account-Based Health Plans. , According to Zane ... a strategy to lower the cost of healthcare without ... medical spending accounts, however, can be confusing. , The ... learn the four main types of ABHPs. It also ...
(Date:8/22/2014)... This report studies the "Sample Preparation Market by ... Kits (Isolation, Purification), By Application (Genomics, Proteomics), by ... 2018" This market was valued at $4,254.8 million ... a CAGR of 5.9% from 2013 to 2018, ... 98 market data Tables and 23 Figures spread ...
(Date:8/22/2014)... Recently, iFitDress.com, a well-known wedding dress manufacturer and ... wedding gowns . In addition to this, the company’s ... are provided with low shipping fees. , He ... new wedding gowns. In our online store, there are ... choose from. What’s more, all of them are extremely ...
(Date:8/22/2014)... 2014 (HealthDay News) -- Many Americans know little about how ... of an outbreak in the United States, a new survey ... worried that there will be a major Ebola outbreak in ... an immediate family member will get sick with the deadly ... School of Public Health poll. However, those opinions don,t ...
(Date:8/22/2014)... NV (PRWEB) August 22, 2014 Mi40x ... uses university-proven research to show people how they can use ... muscle in only a matter of weeks has caught the ... “Ben Pakulski is one of the most well-known bodybuilders in ... the body he has today, that in itself is a ...
Breaking Medicine News(10 mins):Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 2Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 3Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 4Health News:Discounted Wedding Gowns For Sale At Leading Online Shop iFitDress.com 2Health News:Many Americans Harbor Unfounded Fears About Ebola Outbreak: Survey 2Health News:Mi40x: Review Exposes Ben Pakulski’s Guide to Packing on Lean Muscle Fast 2
... a medical device company focused on the treatment of ... Chief,Executive Officer, and Gregory J. Tibbitts, Chief Financial Officer, ... Growth Conference in,New York, NY on Thursday, September 20, ... A live Web cast and recording of the ...
... Sept. 17 John Brooke, General Manager of,Billian,s ... speaking at Dreamforce ,07 Global Gathering, Salesforce.com,s 5th,Annual ... week. Dreamforce is the ultimate gathering of ... base of Salesforce and AppExchance,users spanning industries, roles ...
... commonly used measure for pain screening may only be modestly ... Medicine and the University of North Carolina. In a study ... General Internal Medicine, they evaluate the usefulness of a scale ... pain from 0 (no pain) to 10 (worst pain). ...
... Opening of the 62nd United Nations General Assembly Tomorrow, September ... ... people dying,of hunger every day and governments failing to meet their millennium,commitment to ... food and hunger to play a,central role "on the table" of the 62nd ...
... 17, 2007) Contrary to concerns that restricting work ... patient care or the residents education, a study in ... College of Surgeons found that limiting work hours does ... addition, the study found that the new model improved ...
... Association,Inc. ("SMART"), announced today that it has become ... a not-for-profit, multi-industry,association working to stimulate the understanding, ... The Smart Card Alliance is the sole ... on the impact and value of Smart,cards in ...
Cached Medicine News:Health News:CryoCor to Present at Maxim Group First Annual Growth Conference in New York 2Health News:Billian's HealthDATA GM Speaking on Dreamforce 07 Panel 2Health News:Rating your pain from 0 to 10 might not help your doctor 2Health News:HungerFREE Campaign Tells UN: 'Put food on the table' 2Health News:Study finds limiting work hours for surgical residents enhances training 2Health News:SMART Association Becomes 'Healthcare Council Member' of Smart Card Alliance 2
... is a monoclonal antibody based ... confirmatory identification of Neisseria gonorrhoeae. ... isolated, viable or fresh cultures. ... two minute rotation, a positive ...
Rapid Test Kit...
... The InTray™ GC is a ... detection of both Neisseria gonorrhoeae and ... a long shelf life and is ... system. Simply inoculate, incubate and ...
OneStep Strip Style Gonorrhea Test is a rapid direct binding test for the visual detection of gonorrhea antigen, in the secretory specimen and urine from urogenital system, as an aid in the diagnosis...
Medicine Products: